DECADRON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Decadron, and what generic alternatives are available?
Decadron is a drug marketed by Merck and is included in eight NDAs.
The generic ingredient in DECADRON is dexamethasone acetate. There are thirty-nine drug master file entries for this compound. Additional details are available on the dexamethasone acetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DECADRON?
- What are the global sales for DECADRON?
- What is Average Wholesale Price for DECADRON?
Summary for DECADRON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 8 |
| Raw Ingredient (Bulk) Api Vendors: | 115 |
| Clinical Trials: | 517 |
| Patent Applications: | 4,415 |
| DailyMed Link: | DECADRON at DailyMed |
Recent Clinical Trials for DECADRON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Miami | Phase 3 |
| Merck Sharp & Dohme LLC | Phase 1 |
| Orion Corporation, Orion Pharma | Phase 1 |
US Patents and Regulatory Information for DECADRON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | DECADRON | dexamethasone sodium phosphate | CREAM;TOPICAL | 011983-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Merck | DECADRON | dexamethasone | TABLET;ORAL | 011664-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Merck | DECADRON | dexamethasone sodium phosphate | INJECTABLE;INJECTION | 012071-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for DECADRON
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| AbbVie Deutschland GmbH & Co. KG | Ozurdex | dexamethasone | EMEA/H/C/001140 Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy. |
Authorised | no | no | no | 2010-07-26 | |
| THERAVIA | Neofordex | dexamethasone | EMEA/H/C/004071 Treatment of multiple myeloma. |
Authorised | no | no | no | 2016-03-16 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
